{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:06:03Z","timestamp":1790805963257,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.drudis.2024.104074","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T06:52:31Z","timestamp":1719643951000},"page":"104074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities"],"prefix":"10.1016","volume":"29","author":[{"given":"Jiaojiao","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edeildo Ferreira","family":"da Silva-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.104074_b0005","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3390\/v15091932","article-title":"Treatment emergent dolutegravir resistance mutations in individuals na\u00efve to HIV-1 integrase inhibitors: a rapid scoping review","volume":"15","author":"Tao","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2024.104074_b0010","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/med.21664","article-title":"Medicinal chemistry strategies toward host targeting antiviral agents","volume":"40","author":"Ji","year":"2020","journal-title":"Med Res Rev"},{"key":"10.1016\/j.drudis.2024.104074_b0015","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1021\/acs.jmedchem.3c01543","article-title":"Antiviral protein\u2013protein interaction inhibitors","volume":"67","author":"Markovi\u0107","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104074_b0020","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1039\/D0CS01261K","article-title":"Targeting RNA with small molecules: from fundamental principles towards the clinic","volume":"50","author":"Falese","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2024.104074_b0025","first-page":"38","article-title":"Potential of the other genetic information coded by the viral RNA genomes as antiviral target","volume":"12","author":"Berzal-Herranz","year":"2019","journal-title":"Pharm Basel Switz"},{"key":"10.1016\/j.drudis.2024.104074_b0030","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3390\/v13091882","article-title":"Mutation rates, mutation frequencies, and proofreading-repair activities in RNA virus genetics","volume":"13","author":"Domingo","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2024.104074_b0035","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2024.104074_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15257770.2023.2228841","article-title":"Antisense oligonucleotides: a promising therapeutic option against infectious diseases","volume":"43","author":"Tekinta\u015f","year":"2024","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.drudis.2024.104074_b0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.drudis.2024.104074_b0050","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.104074_b0055","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1093\/nar\/gku184","article-title":"Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides","volume":"42","author":"Ward","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2024.104074_b0060","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/0024-3205(91)90480-Y","article-title":"Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera","volume":"49","author":"Akhtar","year":"1991","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2024.104074_b0065","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.drudis.2024.104074_b0070","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1074\/jbc.274.3.1715","article-title":"Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression","volume":"274","author":"McKay","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.104074_b0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drudis.2017.09.018","article-title":"Locked nucleic acid: modality, diversity, and drug discovery","volume":"23","author":"Hagedorn","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2024.104074_b0080","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1093\/nar\/16.8.3209","article-title":"Physicochemical properties of phospborothioate oligodeoxynucleotides","volume":"16","author":"Stein","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2024.104074_b0085","first-page":"890","article-title":"Pharmacokinetic properties of 2\u2019-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats","volume":"296","author":"Geary","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2024.104074_b0090","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpdd.1154","volume":"11","author":"Han","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.drudis.2024.104074_b0095","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis b: a phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2024.104074_b0100","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.104074_b0105","unstructured":"GSK. Positive data for bepirovirsen from B-Clear phase IIb trial presented at American Association for the Study of Liver Diseases\u2019 Meeting with simultaneous publication in the New England Journal of Medicine. www.gsk.com\/en-gb\/media\/press-releases\/positive-data-for-bepirovirsen-from-b-clear-phase-iib-trial\/ [Accessed June 26, 2024]."},{"key":"10.1016\/j.drudis.2024.104074_b0110","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/j.jhep.2022.11.023","article-title":"Reply to: \u2018Bepirovirsen\/GSK3389404: antisense or TLR9 agonists?\u2019","volume":"78","author":"You","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.104074_b0115","doi-asserted-by":"crossref","first-page":"S873","DOI":"10.1016\/S0168-8278(22)02041-4","article-title":"Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the phase 2a study","volume":"77","author":"You","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.104074_b0120","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/j.jhep.2022.09.002","article-title":"Bepirovirsen\/GSK3389404: antisense or TLR9 agonists?","volume":"78","author":"Vaillant","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.104074_b0125","unstructured":"GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B. www.gsk.com\/en-gb\/media\/press-releases\/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b\/ [Accessed June 26, 2024]."},{"key":"10.1016\/j.drudis.2024.104074_b0130","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/s41591-022-01908-x","article-title":"Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2","volume":"28","author":"Hagey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2024.104074_b0135","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1038\/s41467-022-32216-0","article-title":"An Intranasal ASO therapeutic targeting SARS-CoV-2","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2024.104074_b0140","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1021\/acsnano.9b06333","article-title":"Specific inhibition of viral microRNAs by carbon dots-mediated delivery of locked nucleic acids for therapy of virus-induced cancer","volume":"14","author":"Ju","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2024.104074_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105523","article-title":"Inhibition of chikungunya virus genome replication by targeting essential RNA structures within the virus genome","volume":"211","author":"Prosser","year":"2023","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2024.104074_b0150","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00249-023-01673-w","article-title":"Peptide nucleic acid conjugates and their antimicrobial applications\u2014a mini-review","volume":"52","author":"Tsylents","year":"2023","journal-title":"Eur Biophys J"},{"key":"10.1016\/j.drudis.2024.104074_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1258091","article-title":"Cell-permeable peptide nucleic acid antisense oligonucleotide platform targeting human betacoronaviruses","volume":"14","author":"Park","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2024.104074_b0160","doi-asserted-by":"crossref","first-page":"17473","DOI":"10.3390\/ijms242417473","article-title":"De novo potent peptide nucleic acid antisense oligomer inhibitors targeting SARS-CoV-2 RNA-dependent RNA polymerase via structure-guided drug design","volume":"24","author":"Shehzadi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104074_b0165","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104074_b0170","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2174\/1566523215666150812120547","article-title":"Bifunctional siRNA containing immunostimulatory motif enhances protection against pandemic H1N1 virus infection","volume":"15","author":"Joshi","year":"2015","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.drudis.2024.104074_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2024.104074_b0180","doi-asserted-by":"crossref","first-page":"S665","DOI":"10.1016\/S0168-8278(22)02045-1","article-title":"Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.104074_b0185","doi-asserted-by":"crossref","first-page":"S850","DOI":"10.1016\/S0168-8278(22)01997-3","article-title":"Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver","volume":"77","author":"Thi","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2024.104074_b0190","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219523120","article-title":"Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection","volume":"120","author":"Hariharan","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2024.104074_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105815","article-title":"An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity","volume":"222","author":"Idris","year":"2024","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2024.104074_b0200","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1038\/mtna.2013.33","article-title":"An algorithm for generating small rnas capable of epigenetically modulating transcriptional gene silencing and activation in human cells","volume":"2","author":"Ackley","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.drudis.2024.104074_b0205","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3390\/v14081628","article-title":"Inhibition of Venezuelan equine encephalitis virus using small interfering RNAs","volume":"14","author":"Haikerwal","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2024.104074_b0210","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.omtn.2019.12.018","article-title":"RNA secondary structure motifs of the influenza A virus as targets for siRNA-mediated RNA interference","volume":"19","author":"Piasecka","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.drudis.2024.104074_b0215","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/v13102004","article-title":"Targeting Tat\u2013TAR RNA interaction for HIV-1 inhibition","volume":"13","author":"Alanazi","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2024.104074_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237559","article-title":"Global cataloguing of variations in untranslated regions of viral genome and prediction of key host RNA binding protein-microRNA interactions modulating genome stability in SARS-CoV-2","volume":"15","author":"Mukherjee","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2024.104074_b0225","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl6096","article-title":"Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures","volume":"7","author":"Zafferani","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2024.104074_b0230","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1039\/b702491f","article-title":"Four-stranded nucleic acids: structure, function and targeting of G-quadruplexes","volume":"37","author":"Huppert","year":"2008","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2024.104074_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129085","article-title":"Targeting G-quadruplexes to achieve antiviral activity","volume":"79","author":"Ruggiero","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2024.104074_b0240","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/nar\/gkad1200","article-title":"G-quadruplexes control hepatitis B virus replication by promoting cccDNA transcription and phase separation in hepatocytes","volume":"52","author":"Giraud","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2024.104074_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011095","article-title":"G-quadruplexes formed by varicella-zoster virus reiteration sequences suppress expression of glycoprotein C and regulate viral cell-to-cell spread","volume":"19","author":"Chung","year":"2023","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2024.104074_b0250","doi-asserted-by":"crossref","first-page":"12328","DOI":"10.1093\/nar\/gkac1030","article-title":"Deciphering RNA G-quadruplex function during the early steps of HIV-1 infection","volume":"50","author":"Amrane","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2024.104074_b0255","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/anie.202011419","article-title":"Targeting RNA G-quadruplex in SARS-CoV-2: a promising therapeutic target for COVID-19?","volume":"60","author":"Zhao","year":"2021","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.drudis.2024.104074_b0260","unstructured":"Sun D, Nguyen Q. Arizona Board of Regents on behalf of the University Of Arizona. Quinacrine and derivatives thereof for treatment of viral infections. 2023; WO 2023\/023651 Al."},{"key":"10.1016\/j.drudis.2024.104074_b0265","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/jmv.27622","article-title":"G-quadruplex ligands inhibit chikungunya virus replication","volume":"94","author":"Lv","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.drudis.2024.104074_b0270","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28783","article-title":"Mapping and characterization of G-quadruplexes in monkeypox genomes","volume":"95","author":"Pereira","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.drudis.2024.104074_b0275","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1021\/jacs.8b01233","article-title":"Small molecule targeted recruitment of a nuclease to RNA","volume":"140","author":"Costales","year":"2018","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2024.104074_b0280","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1021\/acscentsci.0c00984","article-title":"Targeting the SARS-CoV-2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders","volume":"6","author":"Haniff","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2024.104074_b0285","article-title":"Chemical-guided SHAPE sequencing (cgSHAPE-Seq) informs the binding Site of RNA-degrading chimeras targeting SARS-CoV-2 5\u2019 untranslated region","author":"Tang","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2024.104074_b0290","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1093\/nar\/gkaa186","article-title":"Selective targeting of mutually exclusive DNA G-quadruplexes: HIV-1 LTR as paradigmatic model","volume":"48","author":"Tassinari","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2024.104074_b0295","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/nar\/gkv1210","article-title":"Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts","volume":"44","author":"Burel","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2024.104074_b0300","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104074_b0305","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-022-00916-0","article-title":"Cryo-EM advances in RNA structure determination","volume":"7","author":"Ma","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2024.104074_b0310","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1039\/D0MD00167H","article-title":"Systematic analysis of the interactions driving small molecule-RNA recognition","volume":"11","author":"Padroni","year":"2020","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.drudis.2024.104074_b0315","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41592-023-01862-7","article-title":"Nano-DMS-MaP allows isoform-specific RNA structure determination","volume":"20","author":"Bohn","year":"2023","journal-title":"Nat Methods"},{"key":"10.1016\/j.drudis.2024.104074_b0320","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41586-023-06091-8","article-title":"Programming inactive RNA-binding small molecules into bioactive degraders","volume":"618","author":"Tong","year":"2023","journal-title":"Nature"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624001995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624001995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:02:30Z","timestamp":1728381750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624001995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1359644624001995"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104074","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104074"}}